MA54521A - Dérivés d'oxopyridine substitués - Google Patents
Dérivés d'oxopyridine substituésInfo
- Publication number
- MA54521A MA54521A MA054521A MA54521A MA54521A MA 54521 A MA54521 A MA 54521A MA 054521 A MA054521 A MA 054521A MA 54521 A MA54521 A MA 54521A MA 54521 A MA54521 A MA 54521A
- Authority
- MA
- Morocco
- Prior art keywords
- oxopyridine derivatives
- substituted oxopyridine
- substituted
- derivatives
- oxopyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018122825 | 2018-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54521A true MA54521A (fr) | 2022-03-30 |
Family
ID=69143542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054521A MA54521A (fr) | 2018-12-21 | 2019-12-18 | Dérivés d'oxopyridine substitués |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3898633A1 (zh) |
| JP (1) | JP2022514303A (zh) |
| KR (1) | KR20210106504A (zh) |
| CN (1) | CN113474348A (zh) |
| AR (1) | AR117435A1 (zh) |
| AU (1) | AU2019407909B2 (zh) |
| BR (1) | BR112021009435A2 (zh) |
| CA (1) | CA3124220A1 (zh) |
| CL (1) | CL2021001613A1 (zh) |
| CO (1) | CO2021007908A2 (zh) |
| CR (1) | CR20210342A (zh) |
| DO (1) | DOP2021000128A (zh) |
| EA (1) | EA202191764A1 (zh) |
| EC (1) | ECSP21043895A (zh) |
| IL (1) | IL283990A (zh) |
| JO (1) | JOP20210161A1 (zh) |
| MA (1) | MA54521A (zh) |
| MX (1) | MX2021007508A (zh) |
| PE (1) | PE20211790A1 (zh) |
| SG (1) | SG11202104384PA (zh) |
| TW (1) | TW202039510A (zh) |
| WO (1) | WO2020127504A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220565T1 (hr) * | 2018-03-15 | 2022-06-10 | Bayer Aktiengesellschaft | Postupak pripreme dva derivata 4-{[(2s)-2-{4-[5-klor-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2-oksopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamida |
| CN114105881B (zh) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | 血小板聚集抑制剂及其制备方法和用途 |
| CN117337170A (zh) | 2021-03-09 | 2024-01-02 | 拜耳公司 | 包含(4s)-24-氯-4-乙基-73-氟-35-甲氧基-32,5-二氧代-14-(三氟甲基)-32h-6-氮杂-3(4,1)-吡啶-1(1)-[1,2,3]三唑-2(1,2),7(1)-二苯七蕃-74-甲酰胺的药物剂型 |
| WO2022189280A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| CN117015535A (zh) | 2021-03-09 | 2023-11-07 | 拜耳公司 | (4s)-24-氯-4-乙基-73-氟-35-甲氧基-32,5-二氧代-14-(三氟甲基)-32h-6-氮杂-3(4,1)-吡啶-1(1)-[1,2,3]三唑-2(1,2),7(1)-5二苯庚烷-74-甲酰胺的结晶形式 |
| CN114560754A (zh) * | 2022-02-25 | 2022-05-31 | 滁州学院 | 一种烷基醇的制备方法 |
| CN116874469B (zh) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物、中间体及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
| WO2008079787A2 (en) | 2006-12-20 | 2008-07-03 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2014160592A2 (en) | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| JP6410819B2 (ja) | 2013-07-23 | 2018-10-24 | バイエル ファーマ アクチエンゲゼルシャフト | 置換オキソピリジン誘導体および第ＸＩａ因子／血漿としてのその使用 |
| JP6368367B2 (ja) | 2013-10-30 | 2018-08-01 | バイエル ファーマ アクチエンゲゼルシャフト | 置換オキソピリジン誘導体 |
| ES2722425T3 (es) | 2014-09-24 | 2019-08-12 | Bayer Pharma AG | (2H)-2-Oxopiridinas como inhibidores del factor XIa para el tratamiento de enfermedades trombóticas |
| EP3197896B1 (de) * | 2014-09-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| ES2712886T3 (es) * | 2014-09-24 | 2019-05-16 | Bayer Pharma AG | Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa |
| JP6517925B2 (ja) | 2014-09-24 | 2019-05-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたオキソピリジン誘導体 |
| ES2694189T3 (es) | 2014-09-24 | 2018-12-18 | Bayer Pharma Aktiengesellschaft | Derivados de oxopiridina sustituidos |
| EP3197880B1 (de) | 2014-09-24 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung |
| CA2979937A1 (en) | 2015-03-19 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| EP3344618A1 (de) | 2015-09-04 | 2018-07-11 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
-
2019
- 2019-12-18 CR CR20210342A patent/CR20210342A/es unknown
- 2019-12-18 CN CN201980091518.1A patent/CN113474348A/zh active Pending
- 2019-12-18 AR ARP190103745A patent/AR117435A1/es unknown
- 2019-12-18 EA EA202191764A patent/EA202191764A1/ru unknown
- 2019-12-18 SG SG11202104384PA patent/SG11202104384PA/en unknown
- 2019-12-18 PE PE2021000903A patent/PE20211790A1/es unknown
- 2019-12-18 MA MA054521A patent/MA54521A/fr unknown
- 2019-12-18 BR BR112021009435-0A patent/BR112021009435A2/pt not_active Application Discontinuation
- 2019-12-18 JO JOP/2021/0161A patent/JOP20210161A1/ar unknown
- 2019-12-18 MX MX2021007508A patent/MX2021007508A/es unknown
- 2019-12-18 CA CA3124220A patent/CA3124220A1/en active Pending
- 2019-12-18 AU AU2019407909A patent/AU2019407909B2/en not_active Ceased
- 2019-12-18 JP JP2021535063A patent/JP2022514303A/ja active Pending
- 2019-12-18 EP EP19832641.5A patent/EP3898633A1/en active Pending
- 2019-12-18 TW TW108146372A patent/TW202039510A/zh unknown
- 2019-12-18 WO PCT/EP2019/085983 patent/WO2020127504A1/en unknown
- 2019-12-18 KR KR1020217022510A patent/KR20210106504A/ko active Search and Examination
-
2021
- 2021-06-14 IL IL283990A patent/IL283990A/en unknown
- 2021-06-16 CO CONC2021/0007908A patent/CO2021007908A2/es unknown
- 2021-06-16 EC ECSENADI202143895A patent/ECSP21043895A/es unknown
- 2021-06-17 CL CL2021001613A patent/CL2021001613A1/es unknown
- 2021-06-18 DO DO2021000128A patent/DOP2021000128A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP21043895A (es) | 2021-07-30 |
| TW202039510A (zh) | 2020-11-01 |
| CA3124220A1 (en) | 2020-06-25 |
| SG11202104384PA (en) | 2021-05-28 |
| IL283990A (en) | 2021-07-29 |
| DOP2021000128A (es) | 2021-09-30 |
| CL2021001613A1 (es) | 2021-12-03 |
| JOP20210161A1 (ar) | 2023-01-30 |
| AR117435A1 (es) | 2021-08-04 |
| EP3898633A1 (en) | 2021-10-27 |
| CN113474348A (zh) | 2021-10-01 |
| JP2022514303A (ja) | 2022-02-10 |
| AU2019407909A1 (en) | 2021-05-27 |
| BR112021009435A2 (pt) | 2021-08-17 |
| KR20210106504A (ko) | 2021-08-30 |
| CR20210342A (es) | 2021-08-09 |
| CO2021007908A2 (es) | 2021-07-19 |
| MX2021007508A (es) | 2021-08-05 |
| PE20211790A1 (es) | 2021-09-09 |
| AU2019407909B2 (en) | 2023-05-25 |
| EA202191764A1 (ru) | 2021-10-22 |
| WO2020127504A1 (en) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| DK3810587T3 (da) | Substituerede alkoxypyridinylindolsulfonamider | |
| DK3687994T3 (da) | Gadolinium-bærende pcta-baserede kontrastmidler | |
| ES2982030T3 (es) | Compuesto multiaziridínico | |
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| MA52948A (fr) | Composés | |
| DK3794042T5 (da) | Anti-muc1-exatecet-antistof-lægemiddelkonjugat | |
| MA51669A (fr) | Composés | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA53003A (fr) | Composés | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| MA49127A (fr) | Dérivés d'indole n-substitués | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
| DK3823970T3 (da) | Yderligere substituerede triazoloquinoxalinderivater | |
| DK3796975T3 (da) | Sulfonylaminobenzamidderivater | |
| MA49704A (fr) | Dérivés d'acide biliaire à marquage isotopique | |
| DK3894410T3 (da) | Substituerede xanthinderivater | |
| MA52934A (fr) | Composés inhibiteurs de l'oga | |
| MA52946A (fr) | Composés | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| MA52936A (fr) | Composés inhibiteurs d'oga | |
| MA52937A (fr) | Composés inhibiteurs d'oga | |
| MA56504A (fr) | Dérivés de pyridin-3-yle |